Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retatrutide - Eli Lilly and Company

Next Previous
Drug Profile

Retatrutide - Eli Lilly and Company

Alternative Names: GGG Tri-agonist - Eli Lilly and Company; GLP-1/GIP/glucagon tri-agonist - Eli Lilly and Company; LY-3437943

Latest Information Update: 30 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Obesity therapies; Peptides; Sleep disorder therapies
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cardiovascular disorders; Obesity; Osteoarthritis; Sleep apnoea syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2025 Eli Lilly and Company plans a phase III TRIUMPH-7 trial for Obesity and Back pain in USA, Canada, Mexico, Argentina and Poland (SC) (NCT07035093)
  • 21 May 2025 Eli Lilly and Company plans a phase I trial for Type 2 diabetes (Treatment-experianced) in Austria in June 2025 (SC) (NCT06982846)
  • 14 May 2025 Eli Lilly and Company plans a phase I trial for Type 2 diabetes mellitus(Treatment-experienced) in Germany(SC) in May 2025 (EudraCT2024-518470-13-00)(NCT06982859)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top